Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BNBX vs BMRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BMRA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–2 Matrix Metrics)
BMRA Overall Winner
6-Pillar Tally: BNBX 2 – 2 BMRA (2 Tie)
Matrix Metrics: BNBX 2 – 5 BMRA
As of Nov 16, 2026, Biomerica Inc (BMRA) is the stronger overall head-to-head candidate over BNB Plus Corp. (BNBX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). BNBX carries a Unified Composite Score of 37.7/100 (SELL) at $0.16 (N/M Forward P/E, -636.4% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin).
- Growth vs. Quality Trade-Off: BMRA earns the overall head-to-head edge with a stronger Unified Composite Score (44.5/100 HOLD vs. BNBX 37.7/100 SELL) and 0.67β · 62% Vol risk profile, whereas BNBX leads top-line expansion (+34.3% YoY revenue growth, 1.27x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: BNBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About BNBX vs BMRA
BNBX
BNB Plus Corp.
$0.16
-56.75% 1D
Market Cap
$2.7M
TTM Revenue
$2.1M
Forward P/E
N/M
Beta / 30D Vol
1.68β · 227% Vol
Unified Composite Score
37.7
SELL
Tech 40.0
Fund 46.0
Flow 50.0
Mom 48.9
Weinstein Technical Phase
Markdown · Sell / avoid
BMRA
Head-to-Head Winner
Biomerica Inc
$1.36
+0.0% 1D
Market Cap
$6.0M
TTM Revenue
$4.3M
Forward P/E
N/M
Beta / 30D Vol
0.67β · 62% Vol
Unified Composite Score
44.5
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (BNBX 2 – 2 BMRA)
1. Valuation Multiples
BNBX
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
1.27x
N/M
EV / Revenue
0.8x
1.1x
2. Growth & Scale
BNBX
Revenue Growth (YoY)
+34.3%
-8.3%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$2.1M
$4.3M
Market Cap
$2.7M
$6.0M
3. Profitability & Quality
BMRA
Gross Margin
46.8%
0.9%
Operating Margin
-636.4%
-125.2%
Net Profit Margin
0.0%
-115.5%
Return on Equity (ROE)
-306.8%
-113.8%
4. Balance Sheet & Cash Flow
BMRA
Cash Generation (TTM)
-$32M EBITDA
-$3.2M
Cash Flow Margin
N/A
-73.5%
Net Cash / Leverage
-$949,091 Net Debt (0.00x D/E)
$1.1M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Asset Management Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: BNBX (2) vs BMRA (5)| Institutional Metric | BNBX | BMRA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.7M | $6.0M | Tie | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +34.3% | -8.3% | BNBX | |
| Operating Margin (TTM) | -636.4% | -125.2% | BMRA | |
| Net Profit Margin | 0.0% | -115.5% | BNBX | |
| Return on Equity (ROE) | -306.8% | -113.8% | BMRA | |
| 52-Week Range Position | 0% ($0–$7) | 5% ($1–$3) | BMRA | |
| Beta / 30D Volatility | 1.68β · 227% Vol | 0.67β · 62% Vol | BMRA | |
| Unified Institutional Score | 37.7 / 100 (SELL) | 44.5 / 100 (HOLD) | BMRA | |
| Trailing 12M Revenue (USD) | $2.1M | $4.3M | Scale | |
| Gross Profit Margin (TTM) | 46.8% | 0.9% | Quality | |
| PEG Ratio & EV / Revenue | 1.27x PEG · 0.8x EV/Rev | N/M PEG · 1.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$32M EBITDA (-$949,091 Net Debt (0.00x D/E)) | -$3.2M ($1.1M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BMRA +51.06 pp
3M Horizon
BMRA +51.24 pp
6M Horizon
BMRA +48.62 pp
1Y Horizon
BMRA +62.36 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BNBX Revenue | BMRA Revenue | BNBX Op. Margin | BMRA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $10M | -169.3% | -46.4% | BMRA |
| FY2020 | $0M | $10M | -649.0% | -41.0% | BMRA |
| FY2021 | $10M | $10M | -147.9% | -104.2% | BMRA |
| FY2022 | $20M | $20M | -76.9% | -24.0% | BMRA |
| FY2023 | $10M | $10M | -81.9% | -135.3% | BNBX |
| FY2024 | $0M | $10M | -646.7% | -117.6% | BMRA |
| FY2025 | $0M | $10M | -750.9% | -96.7% | BMRA |
| FY2026 | N/A | $0M | N/A | -119.5% | BMRA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
BNBX
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BNBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BMRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
BNBX Moat Profile
Cyclical / Execution-Driven Positioning
Asset Management Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
BMRA Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ BNBX vs BMRA Key Questions & Quantitative Answers
As of Nov 16, 2026, Biomerica Inc (BMRA) is the stronger overall head-to-head candidate over BNB Plus Corp. (BNBX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). BNBX carries a Unified Composite Score of 37.7/100 (SELL) at $0.16 (N/M Forward P/E, -636.4% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin). Growth vs. Quality Trade-Off: BMRA earns the overall head-to-head edge with a stronger Unified Composite Score (44.5/100 HOLD vs. BNBX 37.7/100 SELL) and 0.67β · 62% Vol risk profile, whereas BNBX leads top-line expansion (+34.3% YoY revenue growth, 1.27x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BNBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BNBX leads the Growth & Scale pillar: BNBX posts +34.3% YoY revenue growth and +0.0% YoY earnings growth on $2.1M TTM revenue (46.8% gross margin, -636.4% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BNBX cumulative revenue shifted +0.0% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, BNBX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.
BNBX screens cheaper on headline valuation multiples. BNBX trades at N/M Forward P/E, N/M Trailing P/E, 1.27x PEG, and 0.8x EV/Revenue (unreported EBITDA margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BNBX (-306.8% ROE) versus BMRA (-113.8% ROE) capital efficiency.
In options market volatility and institutional positioning, BNBX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.68β · 227% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BMRA vs BNBX · Reverse Pair
BNBX vs AEMD
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal